Thales and L&T Technology Services Expand Collaboration to Provide Innovative Business Models to Customers
Thales, a leading global technology and security provider, has announced a new contract with engineering and R&D firm L&T Technology Services Limited (LTTS). This partnership will bring Thales’s software monetization platform, Thales Sentinel, to LTTS’ customer base, especially in the Hi-tech, Sustainability and Mobility segments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240821145825/en/
© L&T Technology Services Limited
With over two decades of experience in deploying intelligent digital solutions, LTTS leads in optimizing enterprise operations and pioneering platforms in AI, Mobility, Sustainability, and Hi-Tech. LTTS’ advanced AI offerings in next-gen mobility and smart networks are pivotal in building robust digital infrastructures, enhancing safety, efficiency, and sustainability. Now with the Thales Sentinel software licensing and entitlement platform, LTTS will enable its customers to monetize its software solutions by harnessing recurring revenue business models including agile subscriptions and flexible usage-based pricing models.
Damien Bullot, Vice President, Software Monetization Solutions at Thales: “This partnership builds on Thales’s long standing relationship with LTTS, helping their customers unlock the true value and potential of their software products through flexible pricing and subscription models, better compliance, and automated delivery and activation. We look forward to our continued collaboration to ensure their industry-leading AI offers are properly protected and monetized for maximum ROI.”
Under the new contract, LTTS will resell the Thales Sentinel platform to its customer base and group affiliates globally across diverse sectors, including transportation, medical, hi-tech, telecom, and financial services.
Alind Saxena, Executive Director & President, Mobility & Tech at L&T Technology Services: “Our partnership with Thales underscores our commitment to drive innovation and superior solutions across mobility, sustainability, and hi-tech, leveraging their Sentinel platform. Our proficiency in creating cutting-edge digital solutions and our deep understanding of AI will form the backbone of a robust digital infrastructure. We anticipate contributing to a cohesive digital thread throughout the value chain, accelerating market entry, reducing cycle time along with product development costs, and aiding our customers in their journey towards sustainability through improved software monetization potential."
About Thales
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821145825/en/
Contacts
PRESS
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com
PLEASE VISIT
Thales Group -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.thalesgrou
p.com%2Fen&esheet=54111798&newsitemid=20240821145825&lan=en-US&anchor=Thales+Gro
up&index=3&md5=b7bfe84f488f2822557dcf69d9908739
Cloud Protection & Licensing Solutions | Thales Group -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcpl.thalesgrou
p.com%2F&esheet=54111798&newsitemid=20240821145825&lan=en-US&anchor=Cloud+Protec
tion+%26amp%3B+Licensing+Solutions+%7C+Thales+Group&index=4&md5=44b930513072a267
dd250f72eb8abd6f
Cybersecurity Solutions | Thales Group -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.thalesgrou
p.com%2Fen%2Fmarkets%2Ftransverse-markets%2Fcybersecurity-solutions&esheet=54111
798&newsitemid=20240821145825&lan=en-US&anchor=Cybersecurity+Solutions+%7C+Thale
s+Group&index=5&md5=529aa6b3a29cf47d5193347903493d24
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom